

Table SIV. Subgroup analyses assessing associations of sociodemographic characteristics, disease severity and disease duration with satisfaction with the currently prescribed treatment

| Characteristic | TSQM | | | | | | | |
|-----------------------------------|---------------------|--------------|-----------------|-----------------|------------------------------|--------------|---------------------|--------------|
| | Topical therapy | | Phototherapy | | Traditional systemic therapy | | Biologicals | |
| | Mean (SD) | <i>p</i> | Mean (SD) | <i>p</i> | Mean (SD) | <i>p</i> | Mean (SD) | <i>p</i> |
| Gender | | | | | | | | |
| Female | 262.5 (59.9) | 0.746 | 245.3 (55.1) | 0.380 | 270.1 (96.3) | 0.228 | 318.2 (54.6) | 0.424 |
| Male | 269.8 (52.4) | | 273.8 (69.4) | | 301.3 (63.5) | | 326.8 (57.2) | |
| Age | | | | | | | | |
| <50 years | 246.6 (54.8) | 0.005 | 262.9 (46.1) | 0.944 | 276.9 (95.1) | 0.565 | 332.9 (47.7) | 0.174 |
| ≥50 years | 296.5 (40.6) | | 256.9 (89.0) | | 294.7 (69.8) | | 315.4 (61.2) | |
| Psoriasis Area and Severity Index | | | | | | | | |
| 0–5 | 265.7 (58.5) | 0.938 | 265.8 (69.4) | 0.496 | 298.1 (72.1) | 0.040 | 322.5 (58.9) | 0.919 |
| >5 | 269.5 (47.7) | | 243.3 (32.6) | | 236.5 (101.1) | | 326.7 (41.9) | |
| Dermatology Life Quality Index | | | | | | | | |
| 0–5 | 294.8 (38.8) | <0.001 | 340.2 (10.1) | 0.001 | 313.1 (59.7) | <0.001 | 335.9 (48.4) | 0.001 |
| >5 | 233.9 (53.4) | | 236.8 (49.2) | | 228.0 (91.5) | | 291.8 (61.9) | |
| Disease duration | | | | | | | | |
| 0–10 years | 265.1 (62.0) | 0.964 | 274.2 (50.0) | 0.340 | 299.6 (75.0) | 0.439 | 297.8 (78.5) | 0.072 |
| >10 years | 268.3 (49.6) | | 230.1 (84.2) | | 282.4 (82.6) | | 329.4 (47.7) | |
| Psoriatic arthritis | | | | | | | | |
| Yes | 254.3 (12.2) | 0.491 | NA ^a | NA ^a | 230.7 (71.7) | 0.018 | 306.5 (62.7) | 0.032 |
| No | 268.3 (57.9) | | 260.6 (62.4) | | 296.7 (78.1) | | 333.5 (49.3) | |

Treatment Satisfaction Questionnaire for Medication (TSQM) scores were compared with *post hoc* tests (LSD). Significant differences are highlighted in bold.

^aNA: not applicable, because none of the participants with psoriatic arthritis currently received phototherapy.